Epic Bio will focus on developing constructs for targets selected by Kite for use in CAR T-cell therapies directed to blood cancers. Credit: Vladimir Zotov / Shutterstock.com.

Gilead company Kite has signed a research collaboration and licence agreement with Epicrispr Biotechnologies (Epic Bio) for the development of new cancer cell therapies leveraging the latter’s gene regulation platform.

Kite will utilise the licensed technology for modulating genes to improve the functionality of CAR T-cells.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Kite cell biology and translational medicine vice-president David Barrett stated: “Cell-based cancer immunotherapies have reshaped modern cancer care, but we have still only scratched the surface of their potential benefit for patients.

“At Kite, we are committed to developing next-generation CAR T-cell therapies with the goal of reaching more patients with cancer who could benefit.”

Epic Bio will focus on developing constructs for targets selected by Kite to be used in CAR T-cell therapies directed to blood cancers.

See Also:

The company will receive an upfront payment from Kite and is also eligible for development, regulatory and sales milestone payments based on performance.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Epic Bio will also obtain tiered royalties on any approved products that result from the partnership.

Epic Bio CEO Amber Salzman stated: “We are proud to partner with Kite to extend the potential application of Epic Bio’s platform for cancer treatment.

“Epic Bio’s approach is not only promising for in vivo medicines, but may also enable next-generation cell therapies to reach a wide range of patient populations.”